0.06Open0.06Pre Close0 Volume84 Open Interest10.00Strike Price0.00Turnover117.47%IV17.58%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.0760Delta0.0861Gamma201.00Leverage Ratio-0.0224Theta-0.0001Rho-15.28Eff Leverage0.0020Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet